-
Je něco špatně v tomto záznamu ?
Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring
M. Andrs, J. Korabecny, D. Jun, Z. Hodny, J. Bartek, K. Kuca,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25387153
DOI
10.1021/jm501026z
Knihovny.cz E-zdroje
- MeSH
- 1-fosfatidylinositol-3-kinasa chemie metabolismus MeSH
- inhibitory fosfoinositid-3-kinasy MeSH
- inhibitory proteinkinas chemie metabolismus farmakologie MeSH
- lidé MeSH
- molekulární struktura MeSH
- morfoliny chemie MeSH
- protein-serin-threoninkinasy antagonisté a inhibitory chemie metabolismus MeSH
- racionální návrh léčiv MeSH
- signální transdukce účinky léků MeSH
- terciární struktura proteinů MeSH
- vodíková vazba MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metabolism, migration, survival, and responses to diverse stresses including DNA damage. To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied. Despite their different nature, these two kinase families have related origin and share very similar kinase domains. Therefore, chemical inhibitors of these kinases usually carry analogous structural motifs. The most common feature of these inhibitors is a critical hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chemical tool for development of many additional PI3K and PIKK inhibitors. While several PI3K pathway inhibitors have recently shown promising clinical responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclinical development.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022936
- 003
- CZ-PrNML
- 005
- 20250506132728.0
- 007
- ta
- 008
- 150709s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/jm501026z $2 doi
- 035 __
- $a (PubMed)25387153
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Andrs, Martin $u Biomedical Research Center, University Hospital Hradec Kralove , Sokolska 81, 500 05 Hradec Kralove, Czech Republic. $7 gn_A_00006738
- 245 10
- $a Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring / $c M. Andrs, J. Korabecny, D. Jun, Z. Hodny, J. Bartek, K. Kuca,
- 520 9_
- $a Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metabolism, migration, survival, and responses to diverse stresses including DNA damage. To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied. Despite their different nature, these two kinase families have related origin and share very similar kinase domains. Therefore, chemical inhibitors of these kinases usually carry analogous structural motifs. The most common feature of these inhibitors is a critical hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chemical tool for development of many additional PI3K and PIKK inhibitors. While several PI3K pathway inhibitors have recently shown promising clinical responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclinical development.
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a vodíková vazba $7 D006860
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a morfoliny $x chemie $7 D009025
- 650 _2
- $a 1-fosfatidylinositol-3-kinasa $x chemie $x metabolismus $7 D058539
- 650 _2
- $a inhibitory proteinkinas $x chemie $x metabolismus $x farmakologie $7 D047428
- 650 _2
- $a terciární struktura proteinů $7 D017434
- 650 _2
- $a protein-serin-threoninkinasy $x antagonisté a inhibitory $x chemie $x metabolismus $7 D017346
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a inhibitory fosfoinositid-3-kinasy $7 D000081082
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Korabecny, Jan
- 700 1_
- $a Jun, Daniel
- 700 1_
- $a Hodny, Zdenek
- 700 1_
- $a Bártek, Jiří, $d 1953- $7 xx0046271
- 700 1_
- $a Kuca, Kamil
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 58, č. 1 (2015), s. 41-71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25387153 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20250506132727 $b ABA008
- 999 __
- $a ok $b bmc $g 1083275 $s 905929
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 58 $c 1 $d 41-71 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20150709